These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 15661541)

  • 21. Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma.
    Martin P; Furman RR; Coleman M; Leonard JP
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5636s-5642s. PubMed ID: 17875800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Preoperative adjuvant therapy for primary malignant bone tumors].
    Goto T; Okuma T; Nakada I; Hozumi T; Kondo T
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1750-4. PubMed ID: 18030009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Commentary on Wang et al., "Pre-operative chemotherapy with oral tegafur-uracil and leucovorin for rectal cancer" (J Surg Oncol 89: 256-263).
    Kauh J; Johnstone P
    J Surg Oncol; 2005 May; 90(2):106-7. PubMed ID: 15844186
    [No Abstract]   [Full Text] [Related]  

  • 24. Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?
    Stadler WM; Michaelis LC; Ratain MJ
    J Clin Oncol; 2005 Nov; 23(31):8124-5; author reply 8125-6. PubMed ID: 16258115
    [No Abstract]   [Full Text] [Related]  

  • 25. Prostate cancer chemotherapy: emerging from the shadows.
    Roth BJ
    J Clin Oncol; 2005 May; 23(15):3302-3. PubMed ID: 15738529
    [No Abstract]   [Full Text] [Related]  

  • 26. [Combination therapy with S-1 and CDDP for head and neck cancer].
    Fujii M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():150-4. PubMed ID: 16897992
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens.
    Zia MI; Siu LL; Pond GR; Chen EX
    J Clin Oncol; 2005 Oct; 23(28):6982-91. PubMed ID: 16192585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-risk soft tissue sarcoma: clinical trial and hyperthermia combined chemotherapy.
    Issels RD
    Int J Hyperthermia; 2006 May; 22(3):235-9. PubMed ID: 16754344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.
    Karavasilis V; Seddon BM; Ashley S; Al-Muderis O; Fisher C; Judson I
    Cancer; 2008 Apr; 112(7):1585-91. PubMed ID: 18278813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical trials referral resource.
    Anderson BD; Schoenfeldt M
    Oncology (Williston Park); 2005 Jan; 19(1):69-70, 73-4, 78. PubMed ID: 15743152
    [No Abstract]   [Full Text] [Related]  

  • 31. A phase II study of intrapleural immunochemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy, and long-term subcutaneous IL-2 in stage II-III malignant pleural mesothelioma.
    Rusch VW
    Eur J Cardiothorac Surg; 2007 Mar; 31(3):534-5. PubMed ID: 17267238
    [No Abstract]   [Full Text] [Related]  

  • 32. Bladder cancer clinical trials.
    Lerner SP
    Urol Oncol; 2005; 23(4):275-9. PubMed ID: 16018944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Non-small cell lung cancer (NSCLC): the evolution of neo-adjuvant chemotherapy in the last 15 years].
    Santo A; Genestreti G; Fiorio E; Terzi A; Lonardoni A; Calabrò F; Campaldini B; Colaluca P; Molino A; Cetto GL
    Recenti Prog Med; 2006 Apr; 97(4):211-8. PubMed ID: 16729492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant chemotherapy in localized soft tissue sarcomas: still not proven.
    Blay JY; Le Cesne A
    Oncologist; 2009 Oct; 14(10):1013-20. PubMed ID: 19808771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment.
    Vici P; Viola G; Rossi S; Botti C; Vitucci C; Sergi D; Ferranti FR; Saracca E; Di Lauro L; Corsetti S; Foggi P; Fattoruso SI; Lopez M
    Clin Ter; 2008; 159(6):453-6. PubMed ID: 19169608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug repositioning in sarcomas and other rare tumors.
    Lee ATJ; Huang PH; Pollack SM; Jones RL
    EBioMedicine; 2016 Apr; 6():4-5. PubMed ID: 27211532
    [No Abstract]   [Full Text] [Related]  

  • 37. [Drug therapy in the treatment of primary bone tumors].
    Buxó Costa J; Sans-Sabrafen J
    Med Clin (Barc); 1980 May; 74(10):415-9. PubMed ID: 7412435
    [No Abstract]   [Full Text] [Related]  

  • 38. A multinational, multi-tumour basket study in very rare cancer types: The European Organization for Research and Treatment of Cancer phase II 90101 'CREATE' trial.
    Péron J; Marreaud S; Staelens D; Raveloarivahy T; Nzokirantevye A; Flament J; Steuve J; Lia M; Collette L; Schöffski P
    Eur J Cancer; 2019 Mar; 109():192-195. PubMed ID: 30655100
    [No Abstract]   [Full Text] [Related]  

  • 39. Phase I and phase II clinical trials in sarcoma: Implications for drug discovery and development.
    Lee DY; Staddon AP; Shabason JE; Sebro R
    Cancer Med; 2019 Feb; 8(2):585-592. PubMed ID: 30632291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [I. Adjuvant Chemotherapy for Sarcoma of Bone].
    Hiraga H
    Gan To Kagaku Ryoho; 2018 Mar; 45(3):430-433. PubMed ID: 29650899
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.